Cost-effectiveness of photodynamic therapy in age-related macular degeneration;Coste-efectividad de la terapia fotodinámica en la degeneración macular asociada a la edad

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 81, Issue 4, 2006, Pages 199-204

  Muslera Canclini, Elvira ^a   Natal, C ^a  

^a Servicio de Salud del Principado de Asturias   (Spain)

Author keywords

Age related macular degeneration; Cost effectiveness; Photodynamic therapy

Indexed keywords

AGED; ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33750111874     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-485.
2. Foran S, Wang JJ, Mitchell P. Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003; 10: 215-225.
3. Farber MD. National Registry for the Blind in Israel: estimation of prevalence and incidence rates and causes of blindness. Ophthalmic Epidemiol 2003; 10: 267-277.
4. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-572.
5. Jonasson F, Arnarsson A, Sasaki H, Peto T, Sasaki K, Bird AC. The prevalence of age-related maculopathy in Iceland: Reykjavik eye study. Arch Ophthalmol 2003; 121: 379-385.
6. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001; 108: 697-704.
7. Oneill C, Jamison J, McCulloch D, Smith D. Age-related macular degeneration: cost-of-illnes issues. Drugs Aging 2001; 18: 233-241.
8. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD study). Radiation Therapy for Age-related Macular Degeneration. Ophthalmology 1999; 106: 2239-2247.
9. Marcus DM, Sheils W, Johnson MH, McIntosh SB, Leibach DB, Maguire A, et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol 2001; 119: 171-180.
10. Salinas Alamán A, García Layana A, Juberías Sánchez JR, Sánchez Tocino H, Sádaba Echarri LM, Moreno Montañes J. Termoterapia transpupilar en neovascularización subretiniana oculta secundaria a degeneración macular asociada a la edad. Primeros resultados. Arch Soc Esp Oftalmol 2002; 77: 617-622.
11. Oliva G. Terapia fotodinámica en el tratamiento de la degeneración macular asociada a la edad. Informe Técnico realizado por la Agència d'Avaluació de Tecnologia y Recerca Mèdiques. Barcelona: Agència d'Avaluació de Tecnologia y Recerca Mediques; 2002.
12. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
13. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap Report 2. Arch Ophthalmol 2001; 119: 198-207.
14. Rubin GS, Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic therapy (TAP) study group. Effects of verteporfin therapy on contrast sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4. Retina 2002; 22: 536-544.
15. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000; 118: 47-51.
16. Aduriz-Lorenzo P, Ceballos M, Cienfuegos S, Díaz-Varela M, Natal-Ramos C, Muslera-Canclini E. Evaluación de un modelo de alta resolución para el tratamiento de la neovascularización subretiniana (NVSR) con verteporfín en el Principado de Asturias. Rev Calidad Asistencial 2003; 18: 405-467.
17. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108: 2051-2059.
18. Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a sytematic review. Br J Ophthalmol 2004; 88: 212-217.
19. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002; 16: 334-343.
20. Hopley C. Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004; 88: 982-987.
21. Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: The Blue Mountains Eye Study cohort. Arch Ophthalmol 2003; 121 :658-663.